Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the “Guardian Angel of the Human Genome”
February 28, 2011 | Press Releases
Cellceutix Receives Federal Grants for Each of Its Active Research Programs; Total Exceeds $730,000
November 4, 2010 | Press Releases
Cellceutix Completes Final Toxicity Study for Its Cancer Compound; United States Food and Drug Administration IND Application Underway
October 28, 2010 | Press Releases
Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment of Resistant Lung and Breast Cancers
September 28, 2010 | Press Releases
Cellceutix Closing in on Human Trials with Kevetrin™ for Drug-Resistant Cancers as the Company Reports Progress on Toxicity Studies
August 24, 2010 | Press Releases
Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound
July 26, 2010 | Press Releases